Skip to main content

Table 6 The overall results of the study.

From: Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis

Summary of evidence
Outcomes Risk ratio
(95% CI)
P Num. studies Num. of participants Quality of evidence Heterogeneity (H)
Infections 1.00
(0.87 to 1.14)
0.943 10 3,585 Moderate I2<20% not further investigated
Death from infection 1.60
(0.68 to 3.75)
0.279 3 1,161 Very Low I2<20% not further investigated
Febrile neutropenia 1.14
(0.80 to 1.63)
0.496 2 702 Very Low None
Leucopenia Overall 1.24
(1.12 to 1.37)
>0.001 8 2287 Low No within group H after subgroup analysis for line of treatment, between group H P = 0.016
  Untreated 1.20
(1.09 to 1.33)
>0.001 7 2,091   
  Refractory 2.00
(1.34 to 2.99)
0.001 1 196   
Granulocytopenia 1.07
(1.02 to 1.12)
0.008 8 2,381 Low H disappears in metaregression according to mean age
Overall response Overall 1.12
(1.09 to 1.15)
>0.001 14 4,703 Low Persistent strong H in indolent lymphomas and moderate H in aggressive lymphomas after subgroup and metaregression analyses.
  Indolent lymphomas 1.15
(1.11 to 1.19)
>0.001 6 2,417 Low  
  Aggressive lymphomas 1.07
(1.03 to 1.12)
0.002 8 2,286 Moderate  
  1. CI = 95% confidence interval; H = heterogeneity; 95% Num. = number